Study probes homocysteine as a biomarker in equine valve disease
Bottom line
Left-sided valvular heart disease in horses may be associated with higher plasma homocysteine concentrations, according to a new study in Animals that evaluated the biomarker in horses with mitral and aortic valve disease. The paper builds on earlier equine homocysteine work showing the assay has been validated for horses, while prior reviews had concluded that a link between homocysteine and cardiac dysfunction in horses had not yet been demonstrated. In other words, this study appears to move the field from assay validation and theory toward a disease-specific signal in equine cardiology. (mdpi.com)
Why it matters: For veterinary professionals, the practical question is whether homocysteine could become a useful adjunct biomarker alongside echocardiography, murmur characterization, and routine renal and cardiac workups. That would be notable because equine valvular disease is common, especially in middle-aged and older horses, but murmur significance and disease progression can be difficult to judge clinically. Existing equine biomarker research has been mixed: atrial natriuretic peptide has shown poor sensitivity despite some association with left-sided remodeling, while endothelin-1 and aldosterone have shown increases in some horses with cardiac disease or more advanced valvular change. (sciencedirect.com)
What to watch: Whether follow-up studies show homocysteine adds enough diagnostic or prognostic value, beyond echocardiography and existing biomarkers, to justify routine use in horses with suspected left-sided valvular disease. (pubmed.ncbi.nlm.nih.gov)
Key facts
- Study
- A new study in Animals evaluated plasma homocysteine in horses with left-sided valvular heart disease.
- Finding
- Plasma homocysteine may be elevated in horses with left-sided valvular heart disease.
- Disease focus
- The paper focused on mitral and aortic valve disease.
- Prior evidence
- Earlier equine reviews had not yet demonstrated a link between homocysteine and cardiac dysfunction in horses.
- Assay status
- The homocysteine assay had already been validated for horses.
- Clinical context
- Left-sided valvular disease is the form of acquired valve disease most relevant to mitral and aortic regurgitation.
- Use case
- Homocysteine could become an adjunct biomarker alongside echocardiography and routine cardiac workups.
- Next step
- Follow-up studies are needed to test diagnostic or prognostic value in larger cohorts.
A new Animals study suggests plasma homocysteine may be elevated in horses with left-sided valvular heart disease, putting a familiar human cardiovascular biomarker into sharper focus for equine practice. The finding is notable because prior equine literature had identified homocysteine as biologically plausible, but not yet clearly linked to cardiac dysfunction in horses. (mdpi.com)
That context matters. In human medicine, homocysteine has long been studied as a marker tied to endothelial dysfunction, inflammation, thrombogenesis, oxidative stress, and cardiovascular disease. In horses, though, the evidence base has been thin. A 2023 narrative review in Animals said homocysteine research in horses remained limited, noted no demonstrated relationship with cardiac dysfunction in Equidae at that time, and emphasized the need for better reference ranges and disease-specific studies. (mdpi.com)
The new paper appears to answer part of that call by focusing specifically on horses with left-sided valvular disease, the form of acquired valve disease most relevant to mitral and aortic regurgitation. That focus is clinically important because degenerative valvular disease is among the most common acquired structural heart disorders in horses, and left-sided murmurs can be challenging to interpret without echocardiography. Warmblood data and broader equine cardiology references both underscore how common murmurs and valvular regurgitation are, while also showing that not every murmur reflects clinically important disease. (sciencedirect.com)
The study also fits into a broader search for workable equine cardiac biomarkers. Earlier work found plasma atrial natriuretic peptide rises in horses with heart disease associated with altered left-sided chamber dimensions or function, but its diagnostic usefulness was limited by poor sensitivity. Other studies have reported higher aldosterone concentrations in more severely affected horses with valve insufficiency, and increased endothelin-1 in horses with cardiac disease, including those with left atrial enlargement. Taken together, that history suggests biomarker research in equine cardiology has been promising, but still short on a clearly practice-changing test. (pubmed.ncbi.nlm.nih.gov)
I didn’t find a press release or independent expert commentary specifically on this paper, which likely reflects the niche nature of the topic rather than a lack of relevance. But the surrounding literature points to why researchers keep pursuing these markers: equine practitioners need better ways to distinguish incidental murmurs from disease that warrants serial imaging, workload modification, or closer safety assessment. Consensus guidance for equine athletes with cardiovascular abnormalities emphasizes periodic reexamination and case-by-case management when clinically relevant lesions are identified. (pmc.ncbi.nlm.nih.gov)
Why it matters: If homocysteine proves reproducibly associated with left-sided valvular disease severity, remodeling, or progression, it could become a useful add-on test, especially where repeat echocardiography is not immediately available. But the bar for clinical adoption should stay high. Human cardiology literature shows biomarkers can help with risk stratification in left-sided valvular disease, yet even there they generally supplement, rather than replace, imaging-based decision-making. For equine practice, the immediate value is less about changing treatment today and more about opening a path toward better triage, monitoring, and perhaps earlier recognition of horses whose murmurs deserve closer follow-up. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next step is validation in larger cohorts, ideally with clear cutoffs, renal-function adjustment, and correlation with echocardiographic severity, chamber enlargement, exercise tolerance, and outcomes, so clinicians can tell whether homocysteine is just associated with disease or genuinely useful in case management. (mdpi.com)